| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5b5b921ecb9feed8fd280392d09b7276
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_308ab73b3610373b586db1bb1be0dd08 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B2018-00589
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B2018-00577
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B2018-00547
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B2018-00351
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B2018-00619
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B2018-00333
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B2018-00559
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B2018-0063
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B2018-00452 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B18-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-522 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-522
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61B18-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61B18-18 |
| filingDate |
2012-06-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2015-03-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8efa8ec05253610dcaeb1117cf27abf1 |
| publicationDate |
2015-03-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-8968234-B2 |
| titleOfInvention |
Method of using vasoconstrictive agents during energy-based tissue therapy |
| abstract |
A mammal undergoing an energy-based therapy is treated by administering at least one vasoconstrictive agent to the mammal prior to or during the procedure. The at least one vasoconstrictive agent is added in amounts sufficient to reduce or prevent vasodilation. This treatment method increases or promotes the size of the coagulation zone created after energy-based therapy. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9555037-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9271985-B2 |
| priorityDate |
2006-03-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |